An experimental drug to treat Alzheimer’s disease has failed to hit its targets in clinical trials.
The drug company Roche says its potential treatment, crenezumab, did not significantly slow cognitive decline in Alzheimer’s patients compared to a placebo.
That comes after two other Alzheimer’s drugs in clinical trails failed to improve patients’ symptoms earlier this year.
As it turns out, the vast majority of experimental treatments have flopped.
UCSD Alzheimer’s researcher Larry Goldstein said that doesn’t mean it’s time to give up.
“We need to look under as many different stones as possible for successful therapies, and this, I think, again tells us that we should be looking more broadly how we go about treating this terrible disease," Dr. Goldstein explained.
More than 5 million Americans are living with Alzheimer’s. That number is expected to triple by 2050.
There are medications that can temporarily relieve some of the symptoms of Alzheimer's, but there is no cure.
